Anlotinib synergizes with venetoclax to induce mitotic catastrophe in acute myeloid leukemia

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. 1Anlotinib combined with TQB2450 in patients with platinum-resistant or -refractory ovarian cancer: A multi-center, single-arm, phase 1b trial2022 · 39 citations
2. 2A link between mitotic defects and mitotic catastrophe: detection and cell fate2021 · 135 citations
3. 3Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 20212022 · 208 citations
4. 4Searching for Drug Synergy in Complex Dose–Response Landscapes Using an Interaction Potency Model2015 · 913 citations
5. 5Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors2016 · 436 citations